Accessibility Menu
ThermoGenesis logo

ThermoGenesis(OTC) THMO

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 YearN/A
1 Year-99%
1 Month-99%
$0.00
+0.00%
+0.00Today
ThermoGenesis last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-17
ThermoGenesis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-10
1 month-99%USD 0.002026-07-17
3 month-99%USD 0.002026-05-19
Year to date-99%USD 0.002025-12-31
1 year-99%USD 0.002025-08-15
Since inception-100%USD 76,499.941992-05-01

ThermoGenesis Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.61M

Net Income (TTM)

-$14.75M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-29.25 (Low)

Price

$0.00

Volume

4

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 20, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ThermoGenesis

ThermoGenesis Holdings, Inc. is a global innovator in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. Founded in 1986 and based in Rancho Cordova, California, the company offers advanced solutions for medical devices crucial for automated cell processing.

Products and Services
  • AXP II Automated Cell Separation System for isolating stem cells
  • BioArchive Automated Cryopreservation System for long-term storage
  • XP Point-of-Care System for rapid processing of autologous stem cells
Growth Outlook
  • Recent quarterly revenue increased to $2.737 million, showing growth potential
  • Expansion into international markets, including China and the UAE
  • Focus on contract development and manufacturing services for cell therapies
Financial Highlights
  • Trailing twelve months revenue of $10.4 million indicates steady demand
  • Net income for Q1 2024 reported at -$1.856 million, reflecting ongoing investment
  • Cash and cash equivalents at $1.176 million as of March 31, 2024
ThermoGenesis Holdings, Inc. operates in the healthcare sector, specifically within the medical devices industry. The company’s innovative products cater to a growing market for cell-based therapies, which are increasingly recognized for their potential in treating various medical conditions. The recent increase in quarterly revenue suggests a positive trend, while the expansion into international markets may further enhance growth opportunities. Despite reporting a net loss, the company continues to invest in its product offerings and market presence, positioning itself for future success. The financial data indicates a commitment to innovation and development, which may attract potential investors looking for opportunities in the evolving healthcare landscape.
AI Generated • Aug 6, 2026

Industry

Healthcare Equipment and Supplies

Employees

25

CEO

Xiao Chun Xu, PhD, EMBA

Headquarters

Rancho Cordova, CA 95742, US

THMO Financials

Key Financial Metrics (TTM)

Gross Margin

20.44%

Operating Margin

-69.60%

Net Income Margin

-190.31%

Return on Equity

-1367.44%

Return on Capital

-73.96%

Return on Assets

-160.03%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.85M

Volume

4

Avg. Volume

1.38K

Financials (TTM)

Gross Profit

$2.03M

Operating Income

-$6.09M

EBITDA

-$6.94M

Operating Cash Flow

-$3.61M

Capital Expenditure

-$982.00K

Free Cash Flow

-$4.59M

Cash & ST Invst.

$1.18M

Total Debt

$6.93M

ThermoGenesis Performance Analysis

ThermoGenesis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 9,294,000N/A
20222022-12-31USD 10,483,00012.8%
20232023-12-31USD 9,445,000-9.9%
ThermoGenesis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30-11.6%
Q32023-09-30-3.5%
Q42023-12-319.7%
Q12024-03-3113.8%
ThermoGenesis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -43.41N/A
20222022-12-31USD -20.45-52.9%
20232023-12-31USD -7.59-62.9%
ThermoGenesis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3077.6%
Q32023-09-30-58.2%
Q42023-12-31-34.7%
Q12024-03-3176.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2024YOY CHG

Revenue

$2.74M

+6.4%

Gross Profit

$1.20M

+8.8%

Gross Margin

43.92%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

25

N/A

Net Income

-$1.86M

+63.5%

EBITDA

-$215.00K

+78.8%

Quarterly Fundamentals

Name
Q1 2024YOY CHG

Total Cash

$1.18M

-79.9%

Total Debt

$6.93M

-33.0%

Accounts Receivable

$1.15M

+20.3%

Inventory

$1.25M

-63.6%

Long Term Debt

$2.72M

-20.4%

Short Term Debt

$4.21M

-39.2%

Return on Assets

-1.60%

N/A

Return on Invested Capital

12.40%

N/A

Free Cash Flow

-$525.00K

+62.1%

Operating Cash Flow

-$505.00K

+17.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBLGBone Biologics Corporation
$0.61-5.50%
BIMIBIMI International Medical Inc.
$0.00+0.00%
BXRXQBaudax Bio, Inc.
$0.00+0.00%
EDSAEdesa Biotech, Inc.
$4.76-17.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About THMO

What is the current price of ThermoGenesis?

ThermoGenesis is trading at $0.00 per share.

What is the 52-week range for ThermoGenesis?

Over the past 52 weeks, ThermoGenesis has traded between $0.00 and $0.00.

How much debt does ThermoGenesis have?

As of the most recent reporting period, ThermoGenesis reported total debt of $11.28M.

How much cash does ThermoGenesis have on hand?

ThermoGenesis reported $2.00M in cash and cash equivalents in its most recent financial results.

What is ThermoGenesis’s dividend yield?

ThermoGenesis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.